Education
About Us
Working with TipRanks
Follow Us
Kintor Pharmaceutical Ltd (HK:9939)
:9939
9939 Stock Chart & Stats
HK$1.92
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.92
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.05 - HK$3.15
Previous CloseN/A
Volume545.00K
Average Volume (3M)4.99M
Market Cap
HK$1.35B
Enterprise ValueHK$1.16B
Total Cash (Recent Filing)HK$52.86M
Total Debt (Recent Filing)HK$87.40M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding498,660,100
10 Day Avg. Volume2,605,850
30 Day Avg. Volume4,990,601
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.33
Price to Sales (P/S)78.48
P/FCF Ratio-1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing Net Loss And Reduced Cash BurnA materially smaller net loss and reduced cash burn in 2024 improve the company's runway and lower near-term financing pressure. If sustained, this trend increases the chance management funds key clinical programs to value inflection points without immediate dilution, strengthening execution optionality.
Improving Leverage And Lower DebtLower debt relative to equity reduces fixed financing obligations and enhances balance sheet flexibility. An improving debt-to-equity ratio supports greater resilience through clinical cycles and gives management more optionality for non-dilutive funding or strategic partnerships over the medium term.
Focused Clinical-stage Pipeline In Oncology And DermatologyA concentrated R&D focus on androgen-related pathways and oncology/dermatology creates scientific specialization and potential regulatory leverage. A diverse mix of small molecules and biologics across development stages can produce multiple clinical catalysts, reducing single-asset binary risk over the medium term.
Bears Say
Minimal Revenue And Persistent Operating LossesVery low revenue versus sustained operating losses signals the business is far from commercial scale. This structural gap implies continued dependence on financing to support R&D and operations, raising the probability that future growth will be delayed absent successful clinical readouts or partnerships.
Consistent Negative Operating And Free Cash FlowRepeated negative operating and free cash flow necessitate external capital to sustain development. Over time this increases dilution risk, constrains strategic choices, and may force suboptimal licensing or partnership terms if financing windows narrow prior to clinical or commercial milestones.
Equity Erosion And Negative Returns On EquityDeclining equity and persistently negative ROE indicate shareholder value erosion and potential dilution from repeated financings. This undermines capital sustainability and limits the company's ability to raise non-dilutive funds, imposing a long-term constraint on scaling R&D and commercial investments.
Kintor Pharmaceutical Ltd News
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
Kintor Pharmaceutical Ltd lowest stock price was HK$1.05 and its highest was HK$3.15 in the past 12 months.
What is Kintor Pharmaceutical Ltd’s market cap?
Kintor Pharmaceutical Ltd’s market cap is HK$1.35B.
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
Kintor Pharmaceutical Ltd’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Kintor Pharmaceutical Ltd released its earnings results on Aug 28, 2025. The company reported -HK$0.206 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.206.
Is Kintor Pharmaceutical Ltd overvalued?
According to Wall Street analysts Kintor Pharmaceutical Ltd’s price is currently Overvalued.
Does Kintor Pharmaceutical Ltd pay dividends?
Kintor Pharmaceutical Ltd does not currently pay dividends.
What is Kintor Pharmaceutical Ltd’s EPS estimate?
Kintor Pharmaceutical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kintor Pharmaceutical Ltd have?
Kintor Pharmaceutical Ltd has 498,660,100 shares outstanding.
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Kintor Pharmaceutical Ltd reported an EPS of -HK$0.206 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.37%.
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:9939
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kintor Pharmaceutical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.57%
12-Months-Change
Fundamentals
Return on Equity
-54.87%
Trailing 12-Months
Asset Growth
-45.97%
Trailing 12-Months
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Shanghai Haohai Biological Technology Co., Ltd. Class H
―
Options Prices
Currently, No data available
---